Results 141 to 150 of about 21,585 (169)

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

Current Medical Research and Opinion, 2009
Timothy W Morris, Wolfgang Haas, Timothy L Comstock   +2 more
exaly  

Besifloxacin Ophthalmic Suspension, 0.6%: a Novel Topical Fluoroquinolone for Bacterial Conjunctivitis

Advances in Therapy, 2012
Terrence P O'Brien
exaly  

Bacterial conjunctivitis.

Clinical evidence, 2002
Christine, Chung, Elisabeth, Cohen, Justine, Smith   +2 more
openaire   +1 more source

Bacterial conjunctivitis and keratitis

Current Opinion in Ophthalmology, 1990
O. P. van Bijsterveld, O. L.H. van Hemel
openaire   +1 more source

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

Clinical Therapeutics, 2009
Timothy L Comstock
exaly  

Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops

Canadian Journal of Ophthalmology, 2002
W Bruce Jackson
exaly  

[Bacterial conjunctivitis].

Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 1987
K W, Ruprecht, A A, Bialasiewicz
openaire   +1 more source

Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis

Expert Opinion on Pharmacotherapy, 2009
Joseph S Bertino
exaly  

A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis

Current Medical Research and Opinion, 2005
Richard W Yee, Paula Bernstein
exaly  

Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis in Adults and Children

Clinical Drug Investigation, 2012
Timothy W Morris, Timothy L Comstock
exaly